DMAC vs CAPR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DMAC Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Momentum & Technical, Options & Structure while CAPR counters with relative strength in Valuation. Fundamentally, DMAC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CAPR at 78.7x Forward P/E and 0.0% operating margin (-7.9% YoY). In options structure, DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro) against CAPR sits in CONSOLIDATION (89th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DMAC Revenue | CAPR Revenue | DMAC Op. Margin | CAPR Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2017 | N/A | $0M | N/A | -482.4% | CAPR |
| FY2018 | $0M | $0M | -1352.2% | -917.0% | CAPR |
| FY2019 | N/A | $0M | N/A | -769.5% | CAPR |
| FY2020 | N/A | $0M | N/A | -4412.6% | CAPR |
| FY2021 | N/A | $0M | N/A | -8549.9% | CAPR |
| FY2022 | N/A | $0M | N/A | -1163.9% | CAPR |
| FY2023 | N/A | $30M | N/A | -95.6% | CAPR |
| FY2024 | N/A | $20M | N/A | -191.1% | CAPR |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DMAC | CAPR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $503.1M | $595.4M | Larger Scale | CAPR |
| Trailing P/E Ratio Valuation | N/M | 78.7x | Lower Multiple | CAPR |
| Forward P/E Ratio Valuation | N/M | 78.7x | Lower Multiple | CAPR |
| Revenue Growth (YoY) Growth | +0.0% | -7.9% | Higher Growth | DMAC |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -114.6% | -100.5% | Higher ROE | CAPR |
| 52-Week Range Position Momentum | 55% ($5โ$11) | 15% ($3โ$40) | Stronger Trend | DMAC |
| Beta / 30D Volatility Risk Regime | 1.74ฮฒ ยท 98% Vol | 1.52ฮฒ ยท 152% Vol | Lower Realized Risk | DMAC |
| Unified Institutional Score Composite Signal | 46.3 / 100 (HOLD) | 28.0 / 100 (SELL) | Higher Composite | DMAC |